Non-Alcoholic Fatty Liver Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are already enrolled in a lifestyle management program for obesity at one of the participating centres
Who may not be able to join:
- People whose obesity is caused by a specific underlying syndrome or genetic condition
- People who have liver disease caused by something other than obesity, such as a viral infection, an autoimmune condition, or a genetic disorder
- People who drink more than 20 grams of alcohol on average per day (roughly 1.5 to 2 standard drinks) (confirm with trial site)
- People whose liver scan (called a Fibroscan) result was not valid or usable
- People who are taking certain medications known to cause fat build-up or scarring in the liver, such as long-term steroid tablets or methotrexate
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ruth De Bruyne, MD, PhD, University Hospital, Ghent
Phone: 003293322966
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Improvement of liver fibrosis
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.